Journal Information
Vol. 21. Issue 6.
Pages 680-681 (November - December 2017)
Download PDF
More article options
Vol. 21. Issue 6.
Pages 680-681 (November - December 2017)
Letter to the Editor
Open Access
Long-term virologic and immunologic responses on darunavir/ritonavir – containing regimens among highly antiretroviral therapy-experienced patients: 7-year follow-up of a prospective cohort study in São Paulo, Brazil
José E. Vidala,b,
Corresponding author

Corresponding author.
, Ariane M.R. dos Santosa,b, Érique J.F. Peixoto de Mirandaa, Aluísio C. Seguradoa
a Universidade de São Paulo, São Paulo, São Paulo, Brazil
b Instituto de Infectologia Emilio Ribas, São Paulo, São Paulo, Brazil
Article information
Full Text
Download PDF
Figures (1)
Full Text
Dear Editor:

Management of highly antiretroviral therapy (ART)-experienced patients continues to be a challenge, and there are scarce “real-world” data about their long-term virologic and immunologic responses. Darunavir/ritonavir (DRV/r) was included among the antiretroviral drugs available in Brazil in 2008. Since then five Brazilian studies evaluated the effectiveness of salvage therapy, most of them DRV/r-based. In 2013, we published in this journal a single center prospective cohort study where 82.6% of patients achieved HIV RNA <50copies/mL after 48 weeks of treatment.1 Other four Brazilian retrospective observational studies were published showing 74.7–84% of patients with HIV RNA <50copies/mL. Follow-up in all these studies was also limited to 48 weeks.2–5 Herein, we report the results alongside seven years of our cohort in São Paulo. In line with the original report, non-completers were considered as failures in the analysis of virologic response. In 2016, seven years after initiation salvage therapy with DRV/r, 71.7% of patients had HIV RNA <50copies/mL and their CD4 cell counts increased by a mean of 353cells/mm3. Thirty-seven (40.2%) patients had CD4 cell counts above 500cells/mm3. Fig. 1 shows the annual results of viral loads and CD4 cell counts in this cohort. Despite the decrease in the rate of viral suppression after the third year of follow-up, high rates of viral suppression (about 70%) were still maintained afterwards. Interestingly, the increase of CD4 cell counts was steady and persistent throughout follow-up. Among patients on the 7th year of follow-up (n=72), 71 (98.6%) were receiving DRV/r, and 62 (86.1%) were given raltegravir in addition to DRV/r as part of their salvage regimen. Only 18 (25%) patients maintained the baseline regimen, 30 (41.7%) patients needed to discontinue at least one antiretroviral, and 32 (44.4%) patients needed to switch one or more components of their regimen. Our results showed that long-term benefit of ART is possible in middle-income countries, in spite of continuous and new challenges.

Fig. 1.

Long-term virologic (A) and immunologic (B) responses on darunavir/ritonavir – containing regimens among highly ART-experienced patients.

Conflicts of interest

JEV has received honoraria for lectures and travel grants from Janssen-Cilag and Merck Sharp & Dohme. Other authors have no conflicts of interest.

J.E. Vidal, A.T. Song, M.L. Matos, et al.
High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil.
Braz J Infect Dis, 17 (2013), pp. 41-47
M. Schöntag, S. Tenore, P. Ferreira, J. Guinoza, R. Diaz.
High viral load, previous fosamprenavir use and more recent HIV diagnosis correlate with darunavir failure in salvage therapy in Sao Paulo, Brazil.
J Int AIDS Soc, 15 (2012), pp. 18269
F. Biscione, M.R. Westin, K.M. Ribeiro, et al.
Virologic and immunologic effectiveness at 48 weeks of darunavir ritonavir-based regimens in treatment-experienced persons living with HIV1 infection in clinical practice: a multicenter Brazilian cohort.
J Int Assoc Provid AIDS Care, 13 (2014), pp. 63-68
K.M. Ribeiro, F.M. Biscione, M.R. Westin, D.P. Machado, D.B. Greco, U. Tupinambás.
Virologic and immunologic effectiveness of darunavir-basedsalvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study.
Braz J Infect Dis, 18 (2014), pp. 1-7
C. Brites, I. Nóbrega, E.M. Netto.
Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients.
Braz J Infect Dis, 19 (2015), pp. 529-532
Copyright © 2017. Sociedade Brasileira de Infectologia
The Brazilian Journal of Infectious Diseases

Subscribe to our newsletter

Article options